SG11201703824QA - Substituted bridged urea analogs as sirtuin modulators - Google Patents

Substituted bridged urea analogs as sirtuin modulators

Info

Publication number
SG11201703824QA
SG11201703824QA SG11201703824QA SG11201703824QA SG11201703824QA SG 11201703824Q A SG11201703824Q A SG 11201703824QA SG 11201703824Q A SG11201703824Q A SG 11201703824QA SG 11201703824Q A SG11201703824Q A SG 11201703824QA SG 11201703824Q A SG11201703824Q A SG 11201703824QA
Authority
SG
Singapore
Prior art keywords
substituted bridged
sirtuin modulators
urea analogs
bridged urea
analogs
Prior art date
Application number
SG11201703824QA
Other languages
English (en)
Inventor
James Lamond Ellis
Karen Anderson Evans
Ryan Michael Fox
William Henry Miller
Mark Andrew Seefeld
Original Assignee
Glaxosmithkline Intellectual Property (No 2) Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Intellectual Property (No 2) Ltd filed Critical Glaxosmithkline Intellectual Property (No 2) Ltd
Publication of SG11201703824QA publication Critical patent/SG11201703824QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11201703824QA 2014-11-19 2015-11-19 Substituted bridged urea analogs as sirtuin modulators SG11201703824QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462081916P 2014-11-19 2014-11-19
PCT/IB2015/058978 WO2016079710A1 (en) 2014-11-19 2015-11-19 Substituted bridged urea analogs as sirtuin modulators

Publications (1)

Publication Number Publication Date
SG11201703824QA true SG11201703824QA (en) 2017-06-29

Family

ID=54705247

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201703824QA SG11201703824QA (en) 2014-11-19 2015-11-19 Substituted bridged urea analogs as sirtuin modulators

Country Status (21)

Country Link
US (4) US20170355705A1 (es)
EP (4) EP3221322A1 (es)
JP (4) JP2017534663A (es)
KR (4) KR20170083135A (es)
CN (4) CN107207520A (es)
AU (4) AU2015348942B2 (es)
BR (4) BR112017010602A2 (es)
CA (4) CA2968030A1 (es)
CL (1) CL2017001275A1 (es)
CO (1) CO2017004994A2 (es)
CR (1) CR20170209A (es)
DO (1) DOP2017000123A (es)
EA (1) EA201791074A1 (es)
ES (1) ES2823748T3 (es)
IL (1) IL252252A0 (es)
MX (1) MX2017006658A (es)
PE (1) PE20171257A1 (es)
PH (1) PH12017500913A1 (es)
RU (3) RU2017120857A (es)
SG (1) SG11201703824QA (es)
WO (4) WO2016079711A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016086088A2 (en) * 2014-11-25 2016-06-02 Northwestern University Wound healing through sirt1 overexpression
CN108329388A (zh) * 2018-01-18 2018-07-27 天津市湖滨盘古基因科学发展有限公司 一种人的沉默配型信息调节蛋白突变蛋白及其应用
CN108707150B (zh) * 2018-05-14 2021-04-16 江苏惠利生物科技有限公司 一种咪唑并吡嗪医药中间体的制备方法
CN108395436B (zh) * 2018-05-14 2021-01-12 鹤壁市人民医院 一种咪唑并吡嗪医药中间体的制备方法
CN110478339A (zh) * 2019-08-12 2019-11-22 昆明理工大学 紫铆因在制备靶向恢复突变p53构象药物中的应用
WO2021043703A1 (de) * 2019-09-02 2021-03-11 Merck Patent Gmbh Materialien für organische elektrolumineszenzvorrichtungen
CN114890955A (zh) * 2022-06-23 2022-08-12 江西瑞威尔生物科技有限公司 一种n取代吗啉类有机化合物的制备工艺

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
WO2006094210A2 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Tetrahydroquinoxalinone sirtuin modulators
UA108596C2 (xx) 2007-11-09 2015-05-25 Інгібітори пептиддеформілази
WO2011059839A1 (en) * 2009-10-29 2011-05-19 Sirtris Pharmaceuticals, Inc. Bicyclic pyridines and analogs as sirtuin modulators
EP2790701A1 (en) * 2011-12-12 2014-10-22 SMB Innovation Novel heterocyclic compounds useful in sirtuin binding and modulation
BR112015028613A2 (pt) * 2013-05-13 2017-07-25 Glaxosmithkline Llc análogos de uréia com ligações por pontes substituída como moduladores de sirtuína

Also Published As

Publication number Publication date
BR112017010595A2 (pt) 2018-01-02
WO2016079712A1 (en) 2016-05-26
BR112017010599A2 (pt) 2017-12-26
AU2015348942A1 (en) 2017-06-01
MX2017006658A (es) 2018-01-15
EP3221322A1 (en) 2017-09-27
EP3221317A1 (en) 2017-09-27
PH12017500913A1 (en) 2017-12-04
CA2968027A1 (en) 2016-05-26
KR20170087907A (ko) 2017-07-31
BR112017010602A2 (pt) 2017-12-26
CR20170209A (es) 2017-07-17
CL2017001275A1 (es) 2017-12-15
US10072011B2 (en) 2018-09-11
JP2017534662A (ja) 2017-11-24
CN107207521A (zh) 2017-09-26
AU2015348944A1 (en) 2017-06-01
KR20170083134A (ko) 2017-07-17
WO2016079710A1 (en) 2016-05-26
CN107207509B (zh) 2020-04-21
ES2823748T3 (es) 2021-05-10
EA201791074A1 (ru) 2017-10-31
CN107108627A (zh) 2017-08-29
WO2016079709A1 (en) 2016-05-26
CO2017004994A2 (es) 2017-09-20
DOP2017000123A (es) 2017-08-15
AU2015348941A1 (en) 2017-06-01
US20180319810A1 (en) 2018-11-08
AU2015348943A1 (en) 2017-06-01
RU2017120857A (ru) 2018-12-19
CA2968029A1 (en) 2016-05-26
JP2017534665A (ja) 2017-11-24
WO2016079711A1 (en) 2016-05-26
AU2015348942B2 (en) 2018-07-05
JP2017534664A (ja) 2017-11-24
RU2017120858A (ru) 2018-12-19
CA2968030A1 (en) 2016-05-26
KR20170083135A (ko) 2017-07-17
CN107207520A (zh) 2017-09-26
EP3221317B1 (en) 2020-07-22
US20170362234A1 (en) 2017-12-21
RU2017120855A (ru) 2018-12-19
IL252252A0 (en) 2017-07-31
US20170355705A1 (en) 2017-12-14
KR20170083133A (ko) 2017-07-17
EP3220918A1 (en) 2017-09-27
BR112017010601A2 (pt) 2017-12-26
US20190048016A1 (en) 2019-02-14
PE20171257A1 (es) 2017-08-28
JP2017534663A (ja) 2017-11-24
EP3221316A1 (en) 2017-09-27
CN107207509A (zh) 2017-09-26
CA2968032A1 (en) 2016-05-26
JP6806679B2 (ja) 2021-01-06

Similar Documents

Publication Publication Date Title
IL283582A (en) ror - gamma modulators
HK1256599A1 (zh) ROR-γ的調節劑
DK3394033T3 (da) Heterocykliske forbindelser som immunmodulatorer
IL252554A0 (en) A history of mutated 2-anilinopyrimidines as egfr modulators
MA43382A (fr) Modulateurs des récepteurs des chimiokines
DK3294713T3 (da) Substituerede tetrahydroquinolinonforbindelser som ror-gamma-modulatorer
IL248991B (en) Converted dihydroisoquinolinone compounds
DK3131902T3 (da) Forbindelser som ROR-gamma-modulatorer
EP3221312A4 (en) Substituted bridged urea analogs as sirtuin modulators
HK1252613A1 (zh) 作為cot調節劑的6-氨基-喹啉-3-腈
IL252252A0 (en) Transducible bridged urea analogs as sirtuin modulators
ZA201605332B (en) Trpa1 modulators
PL3303291T3 (pl) Modulatory ROR-gamma
AP2016009432A0 (en) Novel compounds
PL3303290T3 (pl) Modulatory ROR-gamma
PL3303293T3 (pl) Modulatory ROR-gamma
IL249267A0 (en) Materials containing carbonitrile and their use for selective modulation of the androgen receptor
IL253096A0 (en) New calcium modulators
PL3319942T3 (pl) MODULATORY ROR-GAMMA (RORγ)
DK3145916T3 (da) Imidazolderivater som formylpeptidreceptormodulatorer
PL2940229T3 (pl) Urządzenie do mocowania elementów drążonych, przykładowo na fasadach
GB201712632D0 (en) Anthelmintic compounds
GB201406022D0 (en) Outrigger pad carrier
GB201512714D0 (en) Receptor modulator compounds
GB201501696D0 (en) Pharamaceutical Compounds